Candesartan in the treatment of arterial hypertension and its cardiovascular complications

Abstract

Candesartan, a selective angiotensin II AT1 receptor
blocker is used in arterial hypertension in monotherapy or
in combined treatment. On the contrary to ACE inhibitors
candesartan does not influence the bradykinine levels
hence incidence of dry cough and angioedema is much
lower. Majority of the hypotensive effect of the drug is
being observed after the first two weeks of chronic therapy
and full influence after 4–6 weeks of regular pharmacotherapy
and does not diminish in longitudinal annual observation.
The publication aims at brief description, in the
light of data from available large clinical trials, of the
candesartan’s hypotensive effectiveness in comparison with
other hypotensive agents or in combination with them, its
influence on left ventricle hypertrophy, heart failure, cerebrovascular
risk and new-onset diabetes incidence.